ClinicalTrials.gg
CompletedNCT04210180EVARUpdated Feb 24, 2022Results posted

Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction

A Phase 2/3 interventional study of Varenicline and e-cigarette in Smoking Cessation and Harm Reduction, sponsored by Rose Research Center, LLC. Completed at 2 sites in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-24.

Sponsored by Rose Research Center, LLC · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.

Enrollment
96th of 110
25 · median 209
Started
2019
with 5 others
Phase 2/3
6 of 110
1 open now
Registered
97th of 110
by date

Among the 110 studies testing varenicline in Smoking Cessation, this one is the 96th largest by enrollment, is one of 6 that started in 2019, is one of 6 in phase 2/3, and was the 97th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing varenicline in Smoking Cessation, or all of them as a file.
02

Study summary

This open-label study will explore the impact of varenicline on the process of switching from combustible cigarettes (CC) to an e-cigarette. Varenicline is currently the most efficacious single pharmacotherapy for smoking cessation, and through its actions as an agonist or partial agonist at various nicotinic acetylcholine receptor subtypes, serves to diminish the rewarding effects of cigarette smoking. Diminishing the rewarding effects of smoking might facilitate the transition from CC to e-cigarettes. On the other hand, varenicline might attenuate the rewarding effects of nicotine-containing e-cigarettes as well, which could hamper the transition. Thus, the study will provide important information about the actions of varenicline on CC as well as e-cigarettes. There is no therapeutic intent in that smokers' nicotine/tobacco dependence will not be treated; the goal is to switch from one form of nicotine/tobacco dependence (CC) to dependence on a different tobacco product (e-cigarettes).

03

Conditions studied

  • Smoking Cessation
  • Harm Reduction
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has signed the ICF and is able to read and understand the information provided in the consent form.
  2. Is 21 to 65 years of age (inclusive) at screening.
  3. Smokes at least 10 commercially available cigarettes per day (no brand restrictions), for the last 12 months.
  4. Has an expired air carbon monoxide reading of at least 10 ppm at screening.
  5. Interested in switching to an electronic cigarette.
  6. Willing and able to comply with the requirements of the study.
  7. Owns a smart phone with text message and data capabilities compatible with necessary surveys.

Exclusion criteria

Exclusion Criteria:

  1. Is unhealthy or cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason) as judged by the Investigator or designated medical staff based on all available assessments from the screening period (e.g., safety laboratory, vital signs, physical examination, Ankle-Brachial Index, , concomitant medications and medical history).
  2. PHQ-9 score greater than 9, or a score greater than 0 on item #9 ("Thoughts that you would be better off dead, or of hurting yourself in some way") at screening.
  3. Planned use of an FDA-approved smoking cessation product during the study.
  4. High blood pressure (systolic > 150 mmHg or diastolic >95 mmHg) at screening.
  5. (BMI) less than 15.0 kg/m2 or greater than 40.0 kg/m2.
  6. Coronary heart disease, structural cardiac disease (including, but not limited to valvular heart disease or cardiac murmurs), cardiac dysrhythmias, syncope, cardiac chest pain, or history of heart attack or heart failure.
  7. Has received psychotherapy or behavioral treatments potentially impacting symptoms of depression, anxiety, or nicotine withdrawal within 30 days of screening, or during the study.
  8. Taking antidepressants, psychoactive medications (e.g. antipsychotics, benzodiazepines, hypnotics) or medications that prolong .
  9. Use of any of these products in the past 30 days: a. Illegal drugs (or if the urine drug screen is positive for cocaine, THC, amphetamines, methamphetamines, or opiates); b. Experimental () drugs that are unknown to subject; c. Chronic opiate use.
  10. Use of smokeless tobacco (chewing tobacco, snuff), cigars (except for "Black \& Mild" cigars or Cigarillos), pipes, hookah, e-cigarettes, nicotine replacement therapy or other smoking cessation treatments within 14 days of screening.
  11. Pregnant or nursing (by self-report) or has a positive pregnancy test.
  12. Enrollment requirements met.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Varenicline plus e-cigarette

    Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. The FDA approved starter kit of varenicline will be provided to participants at V3 (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7) along with additional G6 cartomizers. After the first week of varenicline, participants will receive the FDA-approved standard dose of varenicline (1 mg twice daily) and will continue to receive enough G6 cartomizers for the next 11 weeks.

    Drug: Varenicline · Other: e-cigarette

Interventions

  • 0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7; then 1 mg twice daily for the remaining 11 weeks.

    Also known as: Chantix

  • Othere-cigarette

    Each G6 prefilled cartomizer contains a 50/50 blend nicotine salt with 35mg nicotine strength.

    Also known as: Halo G6

06

What researchers measure

Primary outcomes

  1. Number of Participant Reporting Continuous Complete Switching From Cigarettes to Halo G6

    The primary switching outcome will be smoking abstinence during weeks 8-11 post-switching date. Complete switching from combustible cigarette use at each time point will be defined by a self-report of no cigarette smoking (not even a puff) since the prior session.

    Time frame: Weeks 8-11

  2. Number of Participants Confirmed (by Expired Air CO) to Have Switched From Cigarettes to Halo G6

    The primary switching outcome will be smoking abstinence during weeks 8-11 post-switching date. Complete switching from combustible cigarette use at each time point confirmed by an expired air CO reading of less than 5 ppm.

    Time frame: Weeks 8-11

Secondary outcomes

  1. Number of Participants Reporting Point Abstinence From Smoking Cigarettes at 6 Months Post-Switch

    Point abstinence will be defined by a self-report of no cigarette smoking (not even a puff) in the last seven days at six months post-switch.

    Time frame: 6 months

Other outcomes

  1. Mean Changes in Arterial Flow When Smokers Switch From Cigarettes to E-cigarettes

    Ankle-Brachial Index (ABI) use to evaluate vascular changes when smokers change from cigarettes to e-cigarettes over a 13-week period. Measurements will be obtained using a manual sphygmomanometer and an 8- to 10- MHz doppler ultrasound probe. Subjects will undergo this testing at Visit 1 (baseline data) and at the end of study (Visit 7). Ankle Brachial Index (ABI) is the ratio of the blood pressure in the lower legs to the blood pressure in the arms. The normal range for the ankle-brachial index is between 0.90 and 1.30. An index of 0.41 to 0.90 indicates mild to moderate arterial disease and an index of 0.40 and lower indicates severe disease

    Time frame: Baseline (Visit 1) and 13 weeks (Visit 7)

07

Results

Posted Feb 8, 2022

Participant flow

The study was conducted in both the Raleigh, NC and Charlotte, NC offices of Rose Research Center. Enrollment started on 19 Nov 2019 and ended on 08 Jul 2020.

Participant flow — Overall Study
MilestoneVarenicline Plus E-cigarette
Started25
Completed23
Not completed2
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryNumber of Participant Reporting Continuous Complete Switching From Cigarettes to Halo G6

The primary switching outcome will be smoking abstinence during weeks 8-11 post-switching date. Complete switching from combustible cigarette use at each time point will be defined by a self-report of no cigarette smoking (not even a puff) since the prior session.

Time frame:
Weeks 8-11
Reported as:
Count of participants · Participants
Number of Participant Reporting Continuous Complete Switching From Cigarettes to Halo G6
ParticipantsVarenicline Plus E-cigarette
Number of Participant Reporting Continuous Complete Switching From Cigarettes to Halo G68
PrimaryNumber of Participants Confirmed (by Expired Air CO) to Have Switched From Cigarettes to Halo G6

The primary switching outcome will be smoking abstinence during weeks 8-11 post-switching date. Complete switching from combustible cigarette use at each time point confirmed by an expired air CO reading of less than 5 ppm.

Time frame:
Weeks 8-11
Reported as:
Count of participants · Participants
Number of Participants Confirmed (by Expired Air CO) to Have Switched From Cigarettes to Halo G6
ParticipantsVarenicline Plus E-cigarette
Number of Participants Confirmed (by Expired Air CO) to Have Switched From Cigarettes to Halo G68
SecondaryNumber of Participants Reporting Point Abstinence From Smoking Cigarettes at 6 Months Post-Switch

Point abstinence will be defined by a self-report of no cigarette smoking (not even a puff) in the last seven days at six months post-switch.

Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Participants Reporting Point Abstinence From Smoking Cigarettes at 6 Months Post-Switch
ParticipantsVarenicline Plus E-cigarette
Number of Participants Reporting Point Abstinence From Smoking Cigarettes at 6 Months Post-Switch16
Other pre-specifiedMean Changes in Arterial Flow When Smokers Switch From Cigarettes to E-cigarettes

Ankle-Brachial Index (ABI) use to evaluate vascular changes when smokers change from cigarettes to e-cigarettes over a 13-week period. Measurements will be obtained using a manual sphygmomanometer and an 8- to 10- MHz doppler ultrasound probe. Subjects will undergo this testing at Visit 1 (baseline data) and at the end of study (Visit 7). Ankle Brachial Index (ABI) is the ratio of the blood pressure in the lower legs to the blood pressure in the arms. The normal range for the ankle-brachial index is between 0.90 and 1.30. An index of 0.41 to 0.90 indicates mild to moderate arterial disease and an index of 0.40 and lower indicates severe disease

Time frame:
Baseline (Visit 1) and 13 weeks (Visit 7)
Reported as:
Mean · ratio
Mean Changes in Arterial Flow When Smokers Switch From Cigarettes to E-cigarettes
ratioVarenicline Plus E-cigarette
Mean Changes in Arterial Flow When Smokers Switch From Cigarettes to E-cigarettes-0.05 ± 0.12

Adverse events

Collected over Data were collected during the 13 week study period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Varenicline Plus E-cigarette0/25 (0%)1/25 (4%)22/25 (88%)
Most frequent serious events
Most frequent serious events
EventVarenicline Plus E-cigarette
Allergic Reaction to lidocaineMusculoskeletal and connective tissue disorders1/25
Most frequent other events
Most frequent other events
EventVarenicline Plus E-cigarette
NauseaGastrointestinal disorders10/25
HeadacheNervous system disorders6/25
CoughRespiratory, thoracic and mediastinal disorders5/25
InsomniaNervous system disorders4/25
Nightmares/ Vivid DreamsNervous system disorders3/25
VomitingGastrointestinal disorders2/25
ConstipationGastrointestinal disorders2/25
Agitation/AnxietyPsychiatric disorders2/25
Sore ThroatRespiratory, thoracic and mediastinal disorders2/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)Varenicline Plus E-cigarette
Mean46.92 ± 9.10
Sex: Female, Male
Sex: Female, Male(Participants)Varenicline Plus E-cigarette
Female13
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Varenicline Plus E-cigarette
Hispanic or Latino2
Not Hispanic or Latino23
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Varenicline Plus E-cigarette
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American6
White19
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Varenicline Plus E-cigarette
United States25
08

Study locations

2 sites
  • Rose Research Center
    Charlotte, North Carolina 28262, United States
  • Rose Research Center
    Raleigh, North Carolina 27617, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Oct 2020, 10 months.

Results were first posted in Feb 2022, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2019
First posted
Dec 24, 2019
StartActual
Nov 19, 2019
Primary completionActual
Oct 14, 2020
CompletionActual
Mar 22, 2021
Results first posted
Feb 8, 2022
Last update
Feb 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04210180
Lead sponsor
Rose Research Center, LLC
Collaborators
Foundation for a Smoke Free World INC
Responsible party
Jed Rose (President and CEO, Rose Research Center, LLC) — Principal investigator
First posted
Dec 24, 2019
Start date
Nov 19, 2019
Primary completion
Oct 14, 2020
Completion
Mar 22, 2021
Results posted
Feb 8, 2022
Last update
Feb 24, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion